Utah’s business landscape is rich with professionals who have le...Read More
Social Media and Employers: Friends or Enemies?
The Case for HSAs
Time to Show Up
Make a Move
In the Lab
Rent to Own
Back from the Dead
A Breath of Fresh Air
Travel & Tourism
Catheter Connections, a start-up company co-founded by nurses seeking to reduce deadly hospital-acquired bloodstream infections, announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for a patent that broadly covers the Company’s DualCap technology for disinfecting IV tubing end connectors (a “male luer” connector). This patent will be the fifth in the Company’s U.S. IP portfolio, which provides exclusive patent protection for the male luer disinfecting caps.
The Company was the first to recognize and demonstrate that the IV tubing male luer connector is a vector of microbial contamination and is a significant risk factor for hospital-acquired infections. In its mission to save patient lives, Catheter Connections conceived, developed, manufactures and markets the DualCap System, which includes DualCap ─ the first 510(k) cleared medical device that disinfects male luer connectors, killing the microorganisms known to cause bloodstream infections and protecting the connectors from contamination.
“The issuance of yet another patent for our IV disinfection technology is an important milestone for the Company as we continue expanding our IP portfolio that broadly covers the disinfection of male luer connectors,” said Vicki Farrar, Esq., CEO of Catheter Connections. “Hospitals using the DualCap System are reporting significant improvements in patent safety by reducing IV catheter-related bloodstream infections.”
The DualCap System also includes a component for disinfection of IV luer access valves, which are the female connectors into which an IV tubing male luer fits.